Data released by Oxford University shows that COVID-19 vaccine developed by AstraZeneca and the university can prevent more than 70 per cent of people from getting the virus.
According to the University, interim analysis from its phase three vaccine trial shows that the 70.4 per cent effectiveness comes from combining two doses.
It further revealed that one was 90 per cent effective, while the other was 62 per cent effective, adding that the vaccine is shown to work in different age groups, including the elderly.
In his statement, the Director of the Oxford Vaccine Group, and chief investigator of the Oxford Vaccine Trial, Andrew Pollard, said that the developed vaccine is effective.
He said that the findings show that the university have an effective vaccine that will save many lives, adding that more people could be vaccinated with planned vaccine supply.
Pollard thanked the many volunteers in the trial, and the “hard working and talented team of researchers based around the world.”
In her own comment, a colleague of Pollard and Professor of vaccinology at the university, said that the announcement is a step closer to the end of the COVID-19 pandemic.
The chief executive of AstraZeneca, said that the developed vaccine will be globally available and affordable.